Prader-Willi syndrome (PWS) is a complex multisystem disorder because of errors in genomic imprinting with severe hypotonia, decreased muscle mass, poor suckling, feeding problems and failure to thrive during infancy, growth and other hormone deficiency, childhood-onset hyperphagia, and subsequent obesity. Decreased energy expenditure in PWS is thought to contribute to reduced muscle mass and physical activity but may also relate to cellular metabolism and disturbances in mitochondrial function. We established fibroblast cell lines from six children and adults with PWS and six healthy controls for mitochondrial assays. We used Agilent Seahorse XF extracellular flux technology to determine real-time measurements of several metabolic parameters including cellular substrate utilization, Adenosine Triphosphate (ATP)-linked respiration, and mitochondrial capacity in living cells. Decreased mitochondrial function was observed in the PWS patients compared to the healthy controls with significant differences in basal respiration, maximal respiratory capacity, and ATP-linked respiration. These results suggest disturbed mitochondrial bioenergetics in PWS although the low number of studied subjects will require a larger subject population before a general consensus can be reached to identify if mitochondrial dysfunction is a contributing factor in PWS.
| INTRODUCTION
Prader-Willi syndrome (PWS) is a genetic disorder that is characterized by clinical manifestations involving disturbed growth, development, and clinical findings noted in infancy but continued through adulthood. These findings include weak muscle tone (hypotonia) and mass, poor sucking and infantile feeding difficulties with failure to thrive, growth, and other hormone deficiencies with slow growth, hypogenitalism/hypogonadism, and global developmental delay. Later in childhood, food seeking and hyperphagia lead to obesity. During adolescence, short stature, small hands and feet, delayed puberty, cognitive impairment, and behavioral problems (e.g., temper tantrums, violent outbursts, and obsessive/compulsive behavior) are noted.
Dysmorphic features include bifrontal narrowing, upslanting palpebral fissures, downturned corners of mouth (Angulo, Butler, & Cataletto, 2015; Butler, 1990; Butler, 2011; Butler, 2016; Butler, Lee, & Whitman, 2006; Cassidy, Schwartz, Miller, & Driscoll, 2012; Holm et al., 1993) . PWS is because of errors in genomic imprinting with lack of paternally expressed genes generally from a deletion of the chromosome 15q11-q13 region in about 60% of cases, maternal uniparental disomy 15 (mUPD) with both chromosome 15s from the mother in about 35% and imprinting defects or chromosome 15 translocations in the remaining cases .
PWS is recognized as the most common known cause of marked obesity in humans (Butler, 1990) resulting from chronic imbalance between energy intake and expenditure because of hyperphagia with an inability to vomit, decreased muscle mass, tone, and physical activity with a reduced resting metabolic rate (Butler et al., 2006; Butler, Theodoro, Bittel, & Donnelly, 2007; Hill, Kaler, Spetalnick, Reed, & Butler, 1990) . Body fat in individuals with PWS without growth hormone treatment can account for 40%-50% of their body composition, which is two or three times higher than in the general population (Butler, Meaney, & Palmer, 1986) , about one-third of individuals weigh more than 200% of their ideal body weight (Butler & Meaney, 1987; Meaney & Butler, 1989a , 1989b . Total energy, resting energy, sleeping energy, and active energy expenditure are lower in individuals with PWS than in control individuals without the syndrome (Butler et al., 2007; Hill et al., 1990; Schoeller, Levitsky, Bandini, Dietz, & Walczak, 1988) . Lower physical activity and alteration in lean body mass are thought to be responsible for the lower energy expenditure in PWS (Butler et al., 2007) although data are limited related to metabolic differences or cellular metabolism in PWS (Alsaif et al., 2017) . The complex clinical manifestations of PWS are attributed to the loss of paternally expressed imprinted genes on the chromosome 15q11-q13 region but unexplained downstream changes and regulatory networks involving other genes may play a role. Downstream genes are reported to be affected by the deletion process in PWS and could involve unrecognized metabolic pathways (Bittel, Kibiryeva, Talebizadeh, & Butler, 2003) .
Clinical reports in PWS and PWS mouse models show evidence of metabolic disturbances and differential expression of mitochondrial genes that could contribute to pathophysiology (Yazdi et al., 2013) .
Mitochondria play an important cellular role in energy metabolism by carrying out essential cellular functions including the generation of ATP by oxidative phosphorylation, intracellular Ca 2+ homeostasis, reactive oxygen species biology, synthesis, and catabolism of metabolites with transport to correct locations within the cells for optimal function and for apoptosis (Wallace, 2005 ). An abnormality of any of these processes can lead to energy balance disturbances.
Disturbances in mitochondrial function could contribute to several common features seen in PWS including decreased energy, hypotonia, lower metabolic rate, severe obesity, Type 2 diabetes mellitus, and oxidative stress (Perrone et al., 2016) . However, whether and how mitochondrial functional capacity is altered in PWS is not known. Thus, we undertook a study using living cells (fibroblasts) from subjects with PWS and healthy controls in order to assess the impact of mitochondrial performance using Agilent Seahorse XF extracellular flux technology which allows real-time measurements of several metabolic parameters including cellular substrate utilization, ATP-linked respiration, and mitochondrial capacity (Chavan et al., 2017; Tan et al., 2017) .
| SUBJECTS AND METHODS

| Study participants
Fibroblast cells were established from six patients with PWS and six healthy controls ranging in age from 1 to 29 years for mitochondrial function assays. Fibroblast cells were successfully analyzed with Agilent Seahorse XF technology following manufacturer's recommendation (Seahorse Bioscience, North Billerica, MA) on four subjects with PWS (3-year-old male, 3-year-old female, 7-year-old male, and 29-year-old male) and five controls (1-year-old male, 2-year-old male, 12-year-old male, 21-year-old male, and 31-year-old female). Cells did not adhere properly throughout the assay in three subjects and therefore were unsuccessfully analyzed. Two PWS individuals had genetically confirmed 15q11-q13 deletions and two had maternal disomy 15 (see Table 1 ). 
| Cell preparation for Seahorse assay
To investigate oxygen consumption rates (OCR; as indicator of mitochondrial respiration), the Agilent Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA) was used as previously described (Chavan et al., 2017) . Cells were seeded in collagen treated XF24 cell culture plates at 30,000 cells/well in 100 μL growth medium (DMEM medium containing 10% FBS) and placed in 37 C incubator with 5% CO 2. After 4 hr when the cells adhered to the wells, 150 μL of additional media was added to each well. The plate was kept overnight in the incubator. The next day the plate was prepared as follows for the Seahorse assay: Growth medium from each well was removed leaving 50 μL media in each well, each well was then washed twice with 500 μL prewarmed assay medium (XF base medium supplemented with 25 mM glucose, 2 mM glutamine, and 1 mM sodium pyruvate; pH 7.4) and 500 μL assay media was added making the final volume 550 μL. The plate was then incubated in the 37 C incubator without CO 2 for 1 hr to establish equilibration with the assay medium.
Oligomycin, carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), and rotenone/antimycin A were added to injector ports A, B, and C, respectively. The final concentrations of the injections were as follows: 10 μM oligomycin, 2.7 μM FCCP, 10 μM rotenone, and antimycin A. The cartridge was calibrated by the Seahorse XF24 analyzer and the assay continued using the Mito Stress Test assay protocol as described by Nicholls et al. (2010) . OCR were detected under basal conditions followed by the sequential addition of oligomycin, FCCP followed by rotenone, and antimycin A. This allowed for an estimation of the contribution of individual parameters for basal respiration, proton leak, maximal respiration capacity, spare reserve respiration capacity, nonmitochondrial respiration, and ATP-linked respiration Tan, Xiao, Li, Zeng, & Yin, 2015 ; Figure 1 ).
| RESULTS
| Basal respiration
Information on how mitochondria function in intact cells has largely been derived from assays that measure ongoing bioenergetic profile (Chavan et al., 2017; Tan et al., 2017) . Intracellular mitochondrial function can be determined by the sequential addition of pharmacological inhibitors of oxidative phosphorylation (Brand & Nicholls, 2011; Dranka et al., 2011) to measure the various aspects of mitochondrial respiratory profile. However, for meaningful comparisons between disease and normal cell types, and to avoid ambiguity associated with the differences in cell size, shape or number, we normalized the basal OCR to the total number of live cells (3 × 10 5 cells). In the first series of measurements, the basal oxygen consumption of the cells, which represents the net sum of all processes in the cell capable of consuming O 2 including mitochondria and other oxidases was measured. The
results from these studies demonstrate that in all PWS patientderived cells, oxygen consumption, or basal respiratory rates were significantly reduced (t test; p < .05; Figures 1 and 2 ).
| Coupled or ATP-linked respiration
To test the relative contribution of basal respiration to the demand on the proton motive force (for making either ATP or moving other ions across the inner membrane), we used oligomycin, a pharmacological inhibitor of energy-required processes. Oligomycin inhibits ATP synthase and the decrease in OCR in response to oligomycin is then related to the proportion of mitochondrial activity used to generate ATP (coupled respiration; Ainscow & Brand, 1995) . We found that in response to oligomycin, PWS patient cells, irrespective of age and sex, showed a significant decrease in coupled respiration (t test; p < .05), suggesting a decreased coupling of basal respiration to ATP generation (Figures 1 and 2 ).
| Maximal respiratory capacity and spare reserve capacity
An emerging concept in the energetics field is reserve capacity which can be used as an index of mitochondrial health (Brand & Nicholls, 2011; Dranka et al., 2011; Higdon, Landar, Barnes, & Darley-Usmar, 2012; Zelickson et al., 2011) . By indicating how close a cell is to operating at its bioenergetic limit, predictions can be made regarding the cellular response to stress or increased energy demand. (Figures 1 and 2 ).
| Nonmitochondrial respiration
In addition to mitochondrial respiration, cells use some of the consumed oxygen for nonmitochondrial oxygen consuming processes.
This nonmitochondrial respiration is measured by inhibiting the respiratory chain with antimycin A, either alone or in combination with rotenone, which inhibits mitochondrial complex III and complex I, respectively. Such pharmacological inhibition of electron transport typically inhibits the majority of oxygen consumption in the cell, and the remaining O 2 consumption is attributed to nonmitochondrial oxidases present in the cell. Interestingly, PWS patient nonmitochondrial respiration was significantly decreased (t test; p < .05) in our study suggesting alterations in additional oxidative pathways.
| Proton leak
The addition of oligomycin is assumed to completely eliminate control of respiration by oxidative phosphorylation, and the remaining rate of mitochondrial respiration is then taken to represent the cumulative proton leak that was present prior to addition of oligomycin. An increase in the ATP-linked rate of O 2 consumption would indicate an increase in ATP demand, and a decrease would indicate either low (ATP) demand, a lack of substrate availability, or severe damage to the electron transfer chain (ETC), which would impede the flow of electrons and result in a lower OCR. An increase in apparent proton leak could be because of a number of factors: increased uncoupled activity (Divakaruni & Brand, 2011; Echtay et al., 2002) ; damage to the inner mitochondrial membrane and/or ETC complexes, allowing H+ to leak into the matrix; or there could be electron slippage, which would result in oxygen consumption in the absence of proton translocation (Brown, 1992) . We found that at face value the cells from PWS patients showed a significant decrease in proton leak compared to the control cells. However, under the conditions where basal respiration is significantly different between the experimental groups, it is important to consider the ratio of proton leak compared to basal respiration to quantify the apparent proton leak. Thus, we measured the apparent proton leak in the PWS patient samples compared to controls. We found that the apparent proton leak, as a percentage of basal OCR was significantly higher in the PWS patient cell lines (i.e., 13% for control and 23% for PWS) for both children and adults. These results suggest that the decrease in coupled respiration in PWS cells is probably a result of increased proton leak.
Comparison of PWS genetic subtypes (i.e., 15q11-q13 Type II deletion and maternal disomy 15) showed significantly lower basal respiration, proton leak, and maximal respiratory capacity in the deletion subtype (Figure 3 ). Age and genetic differences were also examined and the control children (n = 3; 3 M, 0 F; age range of 1-12 years) showed significantly higher basal respiration, maximal respiratory capacity, and spare reserve capacity compared with PWS children (n = 3; 2 M, 1 F; age range 3-7 years). Similarly, when comparing an adult control male (31-year-old)
with an adult PWS male (29-year-old) and 1-year-old control male with a 3-year-old PWS male, significantly lower values were found for basal respiration, protein leak, maximal respiratory capacity, spare reserve capacity, and ATP-linked respiration in the PWS subjects (Figure 4 ).
| DISCUSSION
PWS results from loss of paternally expressed imprinted genes from chromosome 15q11-15q13 leading to disturbances in neurodevelopment that manifests as multiple complex phenotypes which A second gene that could impact mitochondrial function is TUBGCP5 which is located in the proximal 15q11.2 BP1-BP2 area within the 15q11-q13 region. It is involved with the cytoskeleton and is deleted in individuals with PWS having the 15q11-q13 Type I deletion (Butler et al., 2006) . One could speculate that fibroblasts from those PWS individuals with this gene deleted may have difficulty with adherence to the cell culture flasks not allowing the mitochondrial assays to be completed. When comparing the PWS genetic subtypes in those with PWS and mitochondrial assay failure, no genetic subtype differences were observed but the number of subjects studied were small and will require further testing. Another important gene to consider in future studies and in relationship to observed differences involved in mitochondrial function without the 15q11-q13 deletion in PWS is POLG. This gene is located on chromosome 15 at the q26.1 band. When disturbed, this gene leads to mitochondrial DNA (mtDNA) depletion syndrome and plays a role as a DNA polymerase required for replication of human mtDNA (Ashley et al., 2008; Filosto et al., 2003) . Patients with mtDNA depletion are reported with decreased activity of mtDNA-encoded respiratory chain complexes (Davidzon et al., 2005) In cells, such as fibroblasts, where secondary effects of uncoupling have no significant consequences, uncoupled rates can report the maximum activity of electron transport and substrate oxidation. A decrease in maximal respiratory activity is a strong indicator of potential mitochondrial dysfunction, consistent with the hypothesis that mitochondrial dysfunction is a significant component of PWS. We observed significant decreases in maximal respiratory capacity in fibroblasts from PWS patients suggesting mitochondrial dysfunction.
Our results indicate disturbed mitochondrial bioenergetics in PWS, although the number of subjects was small in this pilot study. A larger cohort of PWS subjects is needed to replicate our findings and to further characterize if gender, age or PWS genetic subtypes contribute to study observations. In addition, assessment of cellular ATP levels, the expression and activity of respiratory complexes and analysis of mitochondrial metabolites in such cohorts might help in potential therapeutic options in managing PWS and identifying those at a young age requiring metabolic interventions. 
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